Applied Aerospace & Defense, Inc. remains a Buy, but its price target was lowered from $20.75 to $17.85 following guidance cuts. Although the company beat Q3 revenue expectations and reached a record backlog of $1.26 billion covering 75% of 2027 sales, margin contraction and negative free cash flow raise concerns about execution and cash conversion. The company faces challenges in ramping up production and recovering margins. While the valuation suggests significant upside, near-term performance in Q4 and full-year 2027 guidance will be crucial for maintaining investor confidence.
Applied Aerospace & Defense provides context for industrials sector performance on Pluang. For readers following Industrials, as of Nov 12, 2026 23:11 WIB, 77 of 135 US stocks rose and 58 fell. Notable movers include SPCX at USD 144.11 (+3.12%), QXO at USD 13.38 (-3.11%), and UAL at USD 114.75 (-3.06%) with respective Pluang order activities and hold times.
D.A. Davidson raised Riskified's price target to $12, reflecting a 22.2% potential upside from $9.82. The company reported a 41% revenue increase to $115.2 million and adjusted earnings of $0.07 per share, beating estimates. Profitability improved wi...
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
